2 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Raynaud Phenomenon: new trials by email Literature Review of Raynaud Phenomenon trials Research Report on Raynaud Phenomenon
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cold Challenge With C21 in RP C21, Placebo - Raynaud Phenomenon, Systemic Sclerosis | Phase 2 | Completed | Vicore Pharma AB | 20 | 2020-01-03 | 2023-05-18 |
| Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon Udenafil or Amlodipine - Raynaud Phenomenon | Phase 2 / Phase 3 | Completed | Seoul National University Hospital | 29 | 2011-01-01 | 2012-12-11 |
Raynaud Disease (2) · Scleroderma, Systemic (1) · Signs and Symptoms (1)
Cardiovascular Diseases (2) · Embolism and Thrombosis (2) · Livedoid Vasculopathy (2) · Peripheral Vascular Diseases (2) · Skin Diseases (2) · Skin Diseases, Vascular (2) · Skin and Connective Tissue Diseases (2) · Thrombosis (2) · Vascular Diseases (2) · Connective Tissue Diseases (1) · Pathological Conditions, Signs and Symptoms (1)
Amlodipine (1) · compound 21 (1) · udenafil (1)
Seoul National University Hospital (1) · Vicore Pharma AB (1)
South Korea (1) · United Kingdom (1)
Ariane Herrick, MD (1) · Eun Bong Lee, MD PhD (1) · Eun Young Lee, MD PhD (1) · Jin Kyun Park, MD (1)
2019 (1)